Abbvie is out of the portfolio for the time being.
I am already strongly represented in the healthcare sector with Novo and Johnson&Johnson.
In addition, the position was quite small and my exemption order still gives exactly the profit of the share 😅
If Abbvie returns to the 150-170 range, I would possibly add it to my portfolio again.
